GC
KERX

Guggenheim Capital’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Guggenheim Capital’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-493,584
Closed -$4.93M – 3062
2015
Q2 		$4.93M Buy
493,584
+94,673
+24% +$1.02M 0.01% 1169
2015
Q1 		$5.08M Buy
398,911
+118,107
+42% +$1.52M 0.01% 1156
2014
Q4 		$3.97M Buy
280,804
+17,838
+7% +$276K 0.01% 1245
2014
Q3 		$3.62M Buy
262,966
+22,605
+9% +$346K 0.01% 1376
2014
Q2 		$3.7M Sell
240,361
-56,456
-19% -$800K 0.01% 1376
2014
Q1 		$5.06M Buy
296,817
+79,786
+37% +$1.2M 0.01% 1118
2013
Q4 		$2.81M Sell
217,031
-67,870
-24% -$811K 0.01% 1483
2013
Q3 		$2.88M Buy
284,901
+43,888
+18% +$391K 0.01% 1383
2013
Q2 		$1.8M Buy
+241,013
New +$1.88M 0.01% 1600

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Guggenheim Capital's KERX Position: Q3 2015 in Review

Guggenheim Capital sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2015, closing a stake of 493,584 shares — an estimated $4.93M sold.

Guggenheim Capital first reported a position in KERX in Q2 2013 and held it in 9 quarters. The position peaked at $5.08M in Q1 2015. 138 funds tracked by Wall St. Rank hold KERX as of Q3 2015.

  • Guggenheim Capital reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Guggenheim Capital sold 493,584 Keryx Biopharmaceuticals Inc shares in Q3 2015, an estimated $4.93M.
  • Guggenheim Capital first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 9 quarters.
  • Guggenheim Capital's Keryx Biopharmaceuticals Inc position peaked at $5.08M in Q1 2015.
  • 138 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2015.

Based on Guggenheim Capital's 13F filing for Q3 2015, filed 16 Nov 2015.